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T-cell epitope of 3 chain of type IV collagen induces severe
glomerulonephritis.
Background. Anti-glomerular basement membrane (GBM)
glomerulonephritis is among the earliest recognized human
autoimmune diseases. However, the etiology of anti-GBM glo-
merulonephritis remains unclear. We have previously shown
that CD4 T cells, specific to 3 NC1 of type IV collagen
(Col43NC1), were able to induce anti-GBM glomerulonephri-
tis in Wistar-Kyoto (WKY) rats. In the present study, we contin-
ued to map the nephritogenic T cell epitope in Col43NC1.
Methods. Synthetic peptides, which covered Col43NC1,
were used as immunogens to induce glomerulonephritis in
WKY rats. T-cell and B-cell responses to the peptides in the
animals were analyzed.
Results. One potent nephritogenic T-cell epitope, pCol(28-
40) (SQTTANPSCPEGT), was identified. A single immuniza-
tion with pCol(28-40) induced extremely severe glomerulone-
phritis in all 23 rats. Renal pathology revealed nearly 100% of
glomeruli with crescentic lesions or tuft necrosis in 21 animals.
pCol(28-40) elicited a T-cell response to the peptide; T cells
isolated from rats immunized with recombinant Col43NC1
reacted with pCol(28-40). pCol(28-40) elicited a peptide spe-
cific antibody response, which did not react with polypeptide
Col43NC1 or native GBM. An 11-mer peptide, pCol(a30-40)
(Ac-TTANPSCPEGT), was further mapped to be the core of
the T-cell epitope in pCol(28-40). As expected, immunization
with pCol(a30-40) induced severe glomerulonephritis in 10 out
of 19 rats.
Conclusion. Our study not only demonstrated that a single
T-cell epitope of Col43NC1 is sufficient to induce severe
glomerulonephritis, but also provides a unique model for study-
ing T-cell–mediated mechanisms in anti-GBM glomerulone-
phritis pathogenesis.
Glomerulonephritis, a common cause of end-stage re-
nal failure worldwide (for review see [1, 2]), was among
the earliest recognized human autoimmune diseases.
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Historically, antibody-mediated mechanisms have been
believed the major cause of glomerulonephritis, espe-
cially of anti-glomerular basement membrane (GBM)
type [3]. Several seminal works have demonstrated that
the 3 chain noncollagen domain of type IV collagen
(Col43NC1) was a major autoantigen associated with
anti-GBM glomerulonephritis or Goodpasture’s syn-
drome [4, 5]. Immunization with Col43NC1 induced
glomerulonephritis in experimental animals [6]. Several
excellent studies have further mapped the B-cell epi-
topes or immunodominant regions of this antigen [7–9].
Recent studies, however, have revealed that T-cell–
mediated cellular immunity may potentially be a more
important mediator of glomerulonephritis [10, 11]. Aside
from participation as helpers to autoreactive B cells in
T-cell–dependent antibody responses to renal autoanti-
gens, autoreactive T cells may directly contribute to glo-
merular damage. Inflammation with characteristics of de-
layed hypersensitivity, which is typically T-cell–mediated,
has also been described in human and experimental glo-
merulonephritis [12–14]. These glomerular infiltrating
T cells may have been activated, as revealed by their
expression of interleukin-2 (IL-2) receptor and various
T-cell cytokines [15]. The contribution of T cells to glo-
merulonephritis, especially of the proliferative/crescentic
type, has been investigated in animal models either lack-
ing T cells or with interrupted B7/CD28 costimulation
pathway [16–18].
One of the most important questions regarding T-cell
involvement in glomerulonephritis has been whether an-
tigen specific CD4 T cells per se could target renal anti-
gens and initiate glomerular injury [10, 11]. Several groups
have tried to induce anti-GBM glomerulonephritis by
transferring lymphocytes from the animals immunized by
GBM or purified collagens [19, 20]. Others have attempted
to map potential nephritogenic epitope using synthetic
peptides of Col43NC1 [21]. We have developed a rat
model for glomerulonephritis, based on Col43NC1 [22],
a well-defined GBM autoantigen for Goodpasture’s syn-
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drome [4–7]. Transfer of T cells specific to Col43NC1
induced glomerulonephritis in naı¨ve recipients, thus pro-
viding the first evidence that antigen-specific T cells per
se initiate glomerular injury [23]. This suggested that
T-cell epitope(s) of this glomerular autoantigen could
induce glomerulonephritis.
To support our hypothesis, we have identified a 13-mer
peptide derived from Col43NC1 in the present study.
This peptide, which was demonstrated to be a T-cell
epitope of Col43NC1, induced extremely severe glo-
merulonephritis in 100% of experimental rats. Further
investigation showed that an acetylated 11 amino acid se-
quence represented the core of this nephritogenic T-cell
epitope. Thus, a single T-cell epitope of Col43NC1 is suf-
ficient to induce glomerulonephritis. Our finding raises
several interesting issues, including a possibility that glo-
merulonephritis could be a consequence of T-cell molec-
ular mimicry during infections.
METHODS
Antigen preparation
Recombinant Col43NC1 (rCol43NC1) was prepared
as described previously [22]. Peptides were synthesized
on an automatic peptide synthesizer, AMS 422 (Gilson,
Middleton, WI, USA) using Fmoc chemistry, and puri-
fied by reverse-phase C18 column on a preparative high-
performance liquid chromatography (HPLC) (Water,
Millford, MA, USA). Purified peptides were analyzed by
HPLC for purity and mass spectrometry for the correct
sequence. Peptides, exceeding 95% purity, were dis-
solved in milli-Q water at a 1 mmol/L concentration, and
used for immunization or other investigative purposes.
Immunization and glomerulonephritis evaluation
Female Wistar-Kyoto (WKT) rats (4 to 6 weeks of age)
were purchased from Harlan (Indianapolis, IN, USA).
The rats were maintained in the animal facility at the
University of Texas Houston Health Science Center and
allowed to acclimate for a minimum of 3 days. Rats
were immunized with either 300 g of rCol43NC1 or
a peptide (0.125 mol), both emulsified in complete
Freund’s adjuvant (CFA), in one hind footpad and at
the base of tail. In some cases, a boost for peptide injec-
tion was given [0.1 mol of the same peptide in incom-
plete Freund’s adjuvant (ICFA)]. Rats immunized with
CFA alone, or with an irrelevant peptide, CP2 [24],
served as controls.
Glomerulonephritis was evaluated by proteinuria/al-
buminuria, renal histopathology and blood urea nitrogen
(BUN). Random urine samples were monitored daily by
Multstix (Bayer, Pittsburgh, PA, USA). Urine albumin
was semiquantitated by 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (2 L
urine/lane) using bovine serum albumin (BSA) as a stan-
dard. Twenty-four–hour urine samples were collected us-
ing metabolic cages and analyzed as described above.
The experimental animals were sacrificed around 40 to
45 days postimmunization or as indicated. Kidney tissues
fixed in Bouin’s solution were used for hematoxylin and
eosin (H&E) staining, and fixed in 10% formalin for
periodic acid-Schiff (PAS), trichrome, or Jones’ staining.
Portions of the kidney tissues were snap-frozen in liquid
nitrogen for direct immunofluorescence staining. With
selected animals, various tissues were fixed in Bouin’s
for histopathology.
Lymphocyte proliferation assay
Lymphocyte proliferation assay (LPA) was carried out
as previously described [23]. Briefly, lymphocytes were
prepared from immunized rats and CD3 T cells were
isolated with a T-cell enrichment column (RTCC; R&D,
Minneapolis, MN, USA). The purity of isolated T cells
was determined by flow cytometry analyses (FACSCali-
bur, Becton Dickinson, San Jose, CA, USA) after staining
with anti-CD4 phycoerythrin (PE) and antirat immuno-
globulin M (IgM)/G-fluorescein isothiocyanate (FITC)
antibodies (Abs) (Pharmingen, San Diego, CA, USA).
T cells and irradiated syngeneic thymocytes (1:1) were
cultured in 96-well plates at 4  105 cells/well in 200 L
of complete T-cell medium. Peptide (0.3 to 30 mol/L)
was added to each well in triplicate, and purified protein
derivative (PPD) was used as positive control. The cells
were incubated at 37C in a humidified, 5% CO2 atmo-
sphere for 72 hours, pulsed with 3[H]-thymidine (0.5Ci/
well) for 18 hours (ICN, Costa Mesa, CA, USA), and
harvested onto glass fiber filters using a semiautomatic
cell harvester (Skatron Instruments, Sterling, VA, USA).
The incorporated radioactivity was measured by a liquid
scintillation counter (Beckman, Fullerton, CA, USA).
The results were expressed as cpm (mean triplicate
cpm with antigen minus mean triplicate cpm without
antigen), or a stimulation index (ratio between cpm with
and without antigens).
Detection of antibodies
Blood samples were taken from tail veins weekly. The
sera were isolated and kept at –80C until use. For de-
tecting antibody to peptides, a previously described en-
zyme-linked immunosorbent assay (ELISA) was applied
[24]. Briefly, plates were coated with 50 L peptide of
a 10 mol/L in a carbonate buffer (pH 9.5), or by diluted
rCol43NC1 [22]. Serially diluted serum (200 to 10,000)
was added to each well in duplicate. The bound rat IgG
antibodies were detected by horseradish peroxidase
(HRPO)-labeled goat antirat IgG (1:10,000) (Southern
Biotechnology, Birmingham, AL, USA) using O-phenol-
diamine (0.25 mg/mL) as the substrate. The plates were
read on an ELISA reader (Molecular Devices, Sunny-
vale, CA, USA) at 490 nm.
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Western blot was used to detect antibody to the recom-
binant protein or isolated GBM proteins. Briefly, either
recombinant protein (12%) or isolated glomerular pro-
teins (7.5%) were separated on SDS-PAGE under reduced
condition by adding -mercaptoethanol (ME), and trans-
ferred to nitrocellulose membranes. The membranes were
incubated with diluted serum at 1:100 to 1:5000 for the
recombinant protein, and 1:100 for GBM proteins. After
washing with PBS containing 0.05% Tween-20, the blots
were incubated with HRPO-labeled goat antirat IgG
(1:10,000). The reactants were visualized using an en-
hanced chemiluminescence ECL Kit (Pierce Chemical
Co. Rockford, IL, USA).
For detecting antibodies to native GBM, indirect im-
munofluorescence was carried out. Undiluted serum was
incubated with frozen sections of severe combined im-
munodeficiency (SCID) mouse kidney, followed by FITC-
labeled goat antirat IgG or IgM antibodies (1:50) (Southern
Biotechnology, Birmingham, AL, USA). A rat mono-
clonal antibody, SR-13, that reacts with Col43NC1 was
used as a positive control (a kind gift from Dr. Y. Sado,
Okayama, Japan) [25]. The sections were viewed using a
fluorescence microscope (BH-2; Olympus, Tokyo, Japan).
In vitro antibody production
Lymphocytes were isolated from inguinal lymph nodes
of immunized rats 3 weeks after immunization. Under
a similar condition as LPA, the lymphocytes (2  107
cells/mL) were cultured in the presence of immunizing
peptide (5mol/L). Lymphocytes from CFA-immunized
rats served as a control. The supernatant was harvested
after 4 days. IgG and antibody to the peptide in the
supernatants were measured by ELISA [22]. The super-
natant was dialyzed against ammonium carbonate and
lyophilized. The lyophilized powder was resolved in PBS
to 40 g/mL for immunofluorescence against SCID kid-
ney sections. SR-13, with a detecting limit of 0.5 g/mL,
was used as positive control.
RESULTS
Design and synthesis of Col43NC1 peptides
Rat Col43NC1 (Gene Bank # NP058776) was used in
synthesis of peptides. The numbering of amino acid resi-
dues, which included 13 upstream residues, was based
on Minor and Sanes [26]. The last 36 amino acid residues
of Col43NC1 have been mapped as Goodpasture’s
B-cell epitope [7]. Since several groups have been unable
to induce glomerulonephritis in WKT rats using the pep-
tide encoding the 36 amino acid residues, sequences after
the 226th residue, which was included in the last 36
amino acid residues, were excluded [27, 28]. A screen
for potential T-cell epitopes was carried out using a com-
puter program. Fifteen peptides covering Col43NC1
were designed (Fig. 1), each of which contained 20 amino
acid residues on average (range, 19 to 21 amino acid
residues). Based on our previous experience, peptides with
this length would be long enough to include a complete
T-cell epitope. Due to unanticipated difficulty in synthe-
sis of peptide pCol(149-168), this peptide was aban-
doned. Thus, only 14 peptides were successfully synthe-
sized and tested.
Identification of nephritogenic regions
Our first step was to identify the peptides that were
able to induce glomerulonephritis. Animals received one
immunization with one of 14 peptides (three to five rats/
peptide). Two groups of animals, immunized with pCol
(19-38) and pCol(190-209), respectively, were observed
to develop significant proteinuria/albuminuria with he-
maturia starting from day 18 to day 25 (Fig. 2A). Five
more rats were immunized with each peptide to confirm
the same results. The result from pCol(190-209)-immu-
nized rats were uneven, as only three of nine developed
higher proteinuria, while others were almost normal. On
the other hand, immunization with pCol(19-38) led to
more even, though lower, proteinuria in the rats (nine
of nine). Based on the above reasons, we decided to
pursue pCol(19-38) first.
In this study, we only focused on the peptide pCol(19-
38). Although one injection of pCol(19-38) only induced
a mild glomerulonephritis, an additional boost with this
peptide enhanced the severity. The proteinuria approached
around 1500 mg/dL in 8 of 12 rats by day 35 in those
receiving a boost (Fig. 2B). Histopathologic evaluation
of glomerulonephritis in the rats with proteinuria 1000
to 1500 mg/dL revealed crescentic lesions in 30% of
the glomeruli. Rats with modest proteinuria had only
mild renal disease characterized mainly by mesangial
hypercellularity.
pCol(28-40) is a potent nephritogenic epitope
To further narrow down the nephritogenic region in
pCol(19-38), two 13-mer peptides, pCol(19-31) and pCol
(28-40), were synthesized to cover the C- and N-terminals
of pCol(19-38) (Fig. 1). Fortunately, we included two
additional amino acid residues (positions 39 and 40) in
pCol(28-40), which were outside of pCol(19-38). Immu-
nization with pCol(19-31) failed to induce any immune
responses or glomerulonephritis. This suggests that
pCol(19-31) may lack a T-cell epitope.
Surprisingly, a single immunization with pCol(28-40) in-
duced very severe proteinuria/albuminuria, which reached
a plateau at 3888 	 132 mg albumin/dL (range, 3554
to 4125 mg/dL) with proteinuria onset around day 14
postimmunization (Fig. 2B). Daily urinary protein secre-
tion, measured at day 30, approached around 500 mg
with reduced urine volumes (12.25 	 2.18 mL/24 hours)
(Fig. 2C). The proteinuria levels were comparable or
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Fig. 1. Synthetic peptides derived from 3
chain noncollagen domain of type IV collagen
(Col43NC1). Dashed line indicates peptide
having been tested by other groups [27, 28].
Amino acid sequences of pCol(19-38), pCol
(19-31), pCol(28-40), and pCol(a30-40) are
shown. Underlines indicate the residues iden-
tical among mammalian species. The peptide
in gray was not successfully synthesized.
Fig. 2. Proteinuria in rats immunized with
synthetic peptides derived from 3 chain non-
collagen domain of type IV collagen (Col4-
3NC1). (A ) Proteinuria in the rats immunized
by a set of Col43NC1-derived peptides (see
Fig. 1). (B ) Development of proteinuria in
individual rats either immunized/boosted with
pCol(19-38)(dash lines) or single immuniza-
tion with pCol(28-40)(solid line). Arrow indi-
cates the time for boost injection with pCol
(19-38). Average proteinuria from recombi-
nant Col43NC1 (rCol43NC1)-immunized
rats, sampled at day 35, is shown. (C ) Twenty-
four–hour urinary protein secretion in pCol
(28-40) immunized rats sampled at day 30
postimmunization.
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Fig. 3. Glomerulonephritis induced 35 days
after immunization with pCol(28-40). (A )
Kidney section stained with hematoxylin and
eosin (H&E) shows that 100% of glomeruli
were inflamed with fibrin or cellular crescents.
The interstitium was diffusely infiltrated by
lymphocytes. (B ) This higher magnification
shows a glomerulus with a cellular crescent
(arrows) composed of epithelioid cells (H&E).
Lymphocytes were present in both the glo-
meruli and in the interstitium. (C ) In kidney
sections stained with the periodic acid-Schiff
(PAS) method, epithelioid crescents (small
arrows) were evident in Bowman’s space be-
tween the PAS-positive glomerular and capsu-
lar basement membranes. The latter basement
membranes were focally spit by interposed
cells. Deposits of fibrin (large arrow) in cres-
cents and in necrotic foci were also PAS posi-
tive. (D ) Mitotic figures (arrow) were focally
present within crescents (PAS). (E ) Kidney
sections from rats immunized with complete
Freund’s adjuvant (CFA) alone. (F ) Kidney
sections from rats immunized with recom-
binant Col43NC1 (rCol43NC1) (H&E).
Bars 
 50 m.
even higher than those immunized with rCol43NC1
[22](Fig. 2B). Some animals appeared very sick after day
30 and had to be sacrificed before the end of experiments.
Three rats died before day 35. Kidneys from the immu-
nized animals were significantly enlarged (1.30 	 0.42 g
vs. 0.66 	 0.02 g for CFA control) and were tan colored
and ischemic when the rats were sacrificed at day 35
to 45. Nineteen of 23 rats immunized with pCol(28-40)
developed a significant amount of ascites (ranging from
5 to 30 mL) around day 35, compared with only 30% in
rats immunized with rCol43NC1 [22]. Some rats even
developed pleural effusions, which were not observed in
rats immunized with rCol43NC1. BUN sampled at day
35 was greatly elevated in immunized rats (89.0 	 9.8
mg/dL), compared with CFA-immunized rats (16.7 	
2.6 mg/dL).
Renal pathology revealed 100% of the glomeruli were
abnormal in all 23 rats (Fig. 3A). In 21 rats, 95% of
glomeruli were affected with fibrin or proliferative cres-
cent formation or tuft necrosis (Fig. 3 B to D). Cellu-
lar infiltration in the interstitial tissue was significant
(Fig. 3A). These data suggested that pCol(28-40) may
be more potent than rCol43NC1 in glomerulonephritis
induction. The time course for glomerulonephritis devel-
opment was investigated. Mild glomerulonephritis could
be observed as early as day 14 with proteinuria above
50 mg/dL, and glomerulonephritis became prominent
after day 20.
T-cell epitope encoded in pCol(28-40) is responsible
for induction of glomerulonephritis
T cells purified from pCol(28-40) immunized rats re-
sponded to pCol(28-40) (Fig. 4A). These T cells reacted
weakly to pCol(19-38), suggesting the two peptides might
have slightly different T-cell epitope(s). This difference
probably was due to the two additional amino acid residues
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Fig. 4. T cell responses in the rats immunized with pCol(28-40), pCol(19-38) and recombinant Col43NC1 (rCol43NC1). T-cell responses to
different peptides in pCol(28-40) (A ), pCol(19-38) (B ), and rCol43NC1 (C )-immunized rats to different peptides; the response in C is expressed
as a stimulation index.
(39 and 40). Similarly, T cells isolated from pCol(19-38)
immunized rats failed to respond to pCol(28-40), al-
though they reacted strongly to pCol(19-38) itself (Fig.
4B). We next asked whether pCol(28-40) was a T-cell
epitope of Col43NC1. T cells from rCol43NC1-immu-
nized rats were tested against the peptides. The rCo-
l43NC1-reactive T cells responded to pCol(28-40), sug-
gesting that peptide pCol(28-40) shared the same T-cell
epitope with rCol43NC1 (Fig. 4C). However, T cells
from rCol43NC1 reacted weakly with pCol(19-38),
which suggested that pCol(19-38) might not be generated
during the antigen processing of rCol43NC1 (Fig. 4C).
It is coincident with the fact that pCol(19-38) was much
less potent inducer of glomerulonephritis.
Although pCol(28-40) elicited circulating antibody to
the peptide, this antibody did not react with pCol(19-38),
pCol(19-31), or rCol43NC1 (Fig. 5 A and B). On the
other hand, pCol(19-38) induced antibodies not only to
itself and pCol(19-31), but also to rCol43NC1 (Fig. 5
A and B). However, circulating GBM antibody was not
detected by Western blot or indirect immunofluores-
cence in rats either immunized with pCol(19-38) or
pCol(28-40) (Fig. 5C). These data demonstrated that the
B-cell epitope encoded within pCol(28-40) was peptide
specific, but not against polypeptide or native Col43 in
GBM.
To rule out that circulating GBM antibody might have
been absorbed by endogenous GBM, in vitro antibody
production was carried out. Lymphocytes from inguinal
lymph nodes of pCol(28-40)-immunized rats produced
significant amount of IgG antibody to pCol(28-40) (Ta-
ble 1). However, the antibody failed to react with native
GBM, as revealed by immunofluorescence, at 40 g/mL,
which was almost 100-fold higher than detecting limit,
0.5 g/mL, set by SR-13 (see Fig. 5C).
Based on these observations, we concluded that pCol
(28-40) contained a potent nephritogenic T-cell epitope
that induces a severe glomerulonephritis, as well as a
peptide-specific B-cell epitope.
pCol(a30-40) is the core of the nephritogenic
T-cell epitope
It is generally accepted that a 9 to 11 amino acid se-
quence is sufficient to constitute a potential T-cell epitope
restricted by class II major histocompatability complex
(MHC). Because two amino acid residues (positions 39
and 40) at C-terminal were critical, two residues at the
N-terminal were truncated. An 11-mer peptide with ace-
tylated N-terminal, pCol(a30-40), was synthesized and
tested (Fig. 1). This 11-mer peptide elicited a T-cell re-
sponse to itself, as well as to pCol(28-40) (right panel in
Fig. 6A). Similarly, T cells from pCol(28-40) immunized
rats responded to pCol(a30-40)(Fig. 6A, left panel), sug-
gesting that the two peptides probably shared the same
T-cell epitope. However, pCol(a30-40) obviously elicited
a weaker T-cell response than pCol(28-40) (Fig. 6A),
which is coincident with the difference between two pep-
tides in their potency in glomerulonephritis induction.
Both peptides shared a similar B-cell epitope, as revealed
by ELISA (Fig. 6B). pCol(a30-40) induced a lower anti-
body response, probably due to a weaker T-cell response.
We next tested whether pCol(a30-40) was nephrito-
genic. Rats that received a single immunization with
pCol(a30-40) could be divided into two distinct groups:
(1) those with severe glomerulonephritis (10 of 19 rats),
and (2) those with mild glomerular changes in the kid-
neys (9 of 19). Peak of proteinuria ranged from trace to
3600 mg/dL. Severe glomerulonephritis was associated
with proteinuria 3000 mg/dL and kidney enlargement.
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Fig. 5. Circulating antibodies in the rat immunized with pCol(28-40)
and pCol(19-38). (A ) Antibodies to peptides or recombinant Col4-
3NC1 (rCol43NC1) as measured by enzyme-linked immunosorbent
assay (ELISA). (B ) Antibodies to rCol43NC1, as determined by West-
ern blot; the numbers in parentheses are sera dilutions; arrow shows
rCol43NC1. (C ) Antibody to native glomerular membrane (GBM),
as detected by indirect immunofluorescence on severe combined immu-
nodeficiency (SCID) kidney section; SR-13 (2 g/mL) is a Col43NC1-
specific monoclonal antibody; undiluted antisera were used.
Among rats with severe glomerulonephritis, 50% to 95%
of glomeruli had cresentic lesions/glomerular tuft necro-
sis. Two rats developed significant ascites and eventually
died around day 60. Thus, pCol(a30-40) was more potent
than the 20-mer peptide pCol(19-38) in glomerulone-
phritis induction. A peptide without acetylation, pCol
(30-40), was also synthesized and tested. It was slightly
less potent in induction of T-cell response as well as
glomerulonephritis (data not shown).
DISCUSSION
The present study demonstrates that a single T-cell
epitope pCol(28-40) of GBM autoantigen Col43NC1
was sufficient to induce extremely severe glomerulone-
phritis. Along with our previous studies [22, 23], we con-
clude that, in addition to an antibody-mediated mecha-
nism, antigen-specific CD4 T cells are able to initiate
glomerular injury and lead to significant glomerulone-
phritis with a similar clinical and pathologic feature of
human anti-GBM glomerulonephritis. This newly identi-
fied nephritogenic T-cell epitope of Col43NC1 provides
us with a crucial and unique model for further investiga-
tion of T-cell–mediated mechanisms in glomerulonephri-
tis pathogenesis. This nephritogenic T-cell epitope is lo-
cated in a conserved region of Col43NC1. Except one,
all other residues in this epitope are identical among
many mammalian species, including human. Interest-
ingly, our recent experiment showed that this epitope
bound to a human MHC class II molecule, which is
associated with human glomerulonephritis. It suggests
that pCol(28-40) is a potential nephritogenic epitope in
human.
Anti-GBM glomerulonephritis, which is among the
earliest recognized human autoimmune diseases, is not
only a clinically important disease, but also serves as an
excellent model for studying human autoimmune dis-
eases. Identification of Goodpasture’s antigen, Col4-
3NC1, by several groups was a hallmark in studying this
disease [4–9]. Based on those pioneering works, several
exquisite animal glomerulonephritis models have been
developed recently using the GBM-specific collagens as
antigens [6, 20, 27, 29, 30]. With most animal models,
the antigens were either purified native GBM proteins,
or recombinant proteins expressed in mammalian cells
closely resembling the native proteins. It was not surpris-
ing that the antibodies to the host’s GBM were uniformly
induced in these models. However, T-cell responses in
those models were largely unmeasured. Thus, it was dif-
ficult to determine which mechanism, antibody, T cells,
or both, was the major player in mediating the glomeru-
lar injury in those models. Although some models did
use peptides as antigens [21, 27, 28, 30], only one group
was successful in induction of a mild glomerulonephritis
using a keyhole limpet hemocyanin (KLH)-linked 27-
mer peptide derived from Col44 [30]. As the anti-GBM
antibody was detectable in the immunized rats, the in-
duced antibody was considered a mediator of the disease.
Interestingly, one group did not find potent nephrito-
genic epitope(s) using a set of synthetic peptides covering
Col43NC1 [21]. We found that the sequence of our
nephritogenic epitope SQTTANPSCPEGT has been
split between “TT” into two peptides, named as P1 and
P2 in the above study. Thus, none of their peptides con-
tained the intact T-cell epitope pCol(28-40). Another
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Table 1. In vitro antibody production by lymphocytes from immunized rats
Antibody activity
Lymphocyte sourcea IgG secretion (g/2 107 cells) pCol(28-40) (1 g/mL) GBM by IF (40 g/mL)
pCol(28-40)-immunized rat 3.71 0.977 Negative
Complete Freund’s adjuvant (CFA)-immunized rat 0.92 0.007 Not tested
GMB is glomerular basement membrane and IF is immunofluorescence.
a Lymphocytes were isolated from inguinal lymph nodes of immunized rats
Fig. 6. Cross-reactivity of T-cell (A) and anti-
body (B ) elicited by pCol(a30-40) and pCol
(28-40). T-cell responses are measured by
T-cell proliferation assay, and antibody by en-
zyme-linked immunosorbent assay (ELISA)
with peptide-coated plates.
critical reason was that human sequence was used for
synthetic peptide in the above study [21]. Unfortunately,
we have recently showed that human sequence, which dif-
fers at one residue from rats, was not nephritogenic in rats.
Based on the results in our previous studies that the
transfer of T cells specific to rCol43NC1 induced glo-
merulonephritis in naı¨ve recipients [23], we believed that
glomerulonephritis could be induced by T-cell epitope(s)
of this glomerular autoantigen. Indeed, we identified a
potent nephritogenic T-cell epitope, pCol(28-40), with
only 11 amino acid residues in its core region. Although it
was not the focus of this paper, another peptide, pCol(190-
209), with only T-cell epitope, was also able to induce
glomerulonephritis. As compared with many other mod-
els, the unique feature of our model is extremely severe
glomerulonephritis inducible by a single well-defined T-
cell epitope. Our model not only provided additional
evidence to support our previous studies that CD4 T
cells alone may mediate glomerulonephritis, but also
creates a unique tool to study this mechanism. In many
human autoimmune disease models such as experimen-
tal autoimmune encephalomyelitis (EAE), experimental
autoimmune uveoretinitis (EAU), and autoimmune myo-
carditis, establishment of a model based on T-cell epi-
tope(s) has been considered a crucial step to study the
pathogenic mechanisms in these diseases [31–33]. We
believe that our model may serve this purpose in studying
pathogenesis of some type glomerulonephritis.
The T-cell responses to different peptides in the pres-
ent study could be summarized as follows. First, peptide
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pCol(19-38) elicited very strong T-cell response, sug-
gesting that pCol(19-38) contains a strong T-cell epitope.
However, T cells from rCol43NC1-immunized rats re-
sponded weakly to pCol(19-38). It was coincident with
that pCol(19-38) only induced mild glomerulonephritis.
Second, pCol(28-40), which was a weaker T-cell epitope
itself, was much more potent in glomerulonephritis in-
duction than pCol(19-38). However, T cells from rCo-
l43NC1-immunized rats responded to pCol(28-40), sug-
gesting that pCol(28-40) shares the same T-cell epitope
of Col43NC1. Thus, the potency of a peptide in induc-
tion of glomerulonephritis is determined by whether the
T-cell epitope is shared with Col43NC1. Processing of
endogenous antigens in renal tissue may only generate
the T-cell epitope such as pCol(28-40). While pCol(19-
38) might be a strong T-cell epitope itself, but a “cryptic”
epitope for native Col43 [34]. It means that the T-cell
epitope included in pCol(19-38) might not be generated
during antigen processing. This phenomenon has been
well documented in many other T-cell–mediated autoim-
mune diseases models [35]. The importance of the two
amino acid residues (positions 39 and 40) have been
further demonstrated recently. Substitutions at the two
residues indeed resulted in alternation of T-cell epitope
activity of pCol(28-40).
Anti-GBM antibody has been demonstrated to cause
glomerulonephritis. We carefully investigated whether
the antibody elicited by nephritogenic peptides reacted
with native GBM proteins. Unlike a protein antigen, a
short peptide elicits a much simpler monospecific anti-
body response. Our investigation showed that pCol(19-
38) elicited an antibody recognizing either the peptide
itself or rCol43NC1. On the other hand, both pCol(28-
40) and pCol(a30-40) failed to induce any antibody pro-
duction to rCol43NC1, although the peptide did induce
antibody to the peptides. Although the monospecific
antibodies in circulation elicited by all three peptides
[pCol(19-38), pCol(28-40), and pCol(a30-40)] could be
detected in high titers, none reacted with native GBM.
These data suggest that all three peptides may contain
B-cell epitopes specific to the peptides and/or to the
polypeptide. The results were confirmed by in vitro anti-
body production, in which possible interference of en-
dogenous GBM was ruled out. In fact, a few studies had
made antibodies to several collagens by either synthetic
peptides or recombinant proteins. The produced anti-
bodies may not react with native proteins, as they stained
GBM only after treatment of the samples at low pH and
high concentration of urea [26, 36]. Using overlapping
synthetic peptides covering NC1 of Col41 and 3
chains, linear B-cell epitopes have been mapped [37].
However, none of Goodpasture’s sera showed activities
to Col43 peptides, suggesting that Col43NC1 may lack
linear epitopes. In fact, a conformational epitope of Col-
43NC1 has been identified through an elegant muta-
genesis study [8].
Our finding that a single T-cell epitope is sufficient to
induce severe glomerulonephritis raises the possibility
that T-cell epitope mimicry may link glomerulonephritis
etiology with infections. Several prior studies have pro-
posed molecular mimicry as a link between infections
and glomerulonephritis without any experimental sup-
port [38]. Molecular mimicry has been suspected as a
possible mechanism for breaking immune tolerance and
causing human autoimmune diseases [39, 40]. T-cell epi-
tope mimicry is more attractive because a T-cell epitope
depends primarily on the linear sequence of less than 15
amino acid residues. It is well known that many cases
of glomerulonephritis are closely associated with various
infectious agents, ranging from hepatitis C virus to ma-
laria [41]. Although the glomerulonephritis associated
with these infections is pathogenically different, T cells
are believed to play important roles in pathogenesis.
Therefore, it will be interesting to determine whether
T-epitope mimicry during infections, especially minor
infections, is a possible cause of glomerulonephritis, since
antigen-specific T cells alone have been proven to initiate
glomeruli injury. Our model may be used for the explora-
tion of T-cell molecular mimicry in glomerulonephritis.
In fact, we have identified several critical residues for
T-cell epitope pCol(28-40). We will search for mimicking
microbial T-cell epitope based on those residues.
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